In the ibrutinib-obinutuzumab arm, factors associated with an increase in cytokine and chemokine levels included splenomegaly (IL-6, IL-8, MCP-1, MIP-1α, TNFα), lower hemoglobin levels (IL-8), higher absolute neutrophil count (IL-8, MCP-1, MIP-1α, TNFα), and higher absolute lymphocyte count (IFNγ, IL-6, IL-8, MCP-1, MIP-1α, TNFα). This evidence concerns the gene IL6 and Splenomegaly.